Introduction: This study reports the oncological outcome of a non-selected series of patients with human papillomavirus(HPV)-positive and -negative oropharyngeal squamous cell carcinoma (OSCC) preferentially managed with upfront surgery.
Methods: Consecutive OSCC cases (n = 378) diagnosed from 2000 to 2010 in our department were evaluated for risk factors, HPV association, therapy and overall survival (OS). HPV status was determined by combined DNA and p16 testing, and treatment was defined as the first course of treatment with any kind of surgery (upfront surgery) or primary chemoradiotherapy. OS of HPV-associated and HPV-negative patients was compared using Kaplan-Meier and multivariable Cox regression analyses.
Results: The majority of OSCC patients (215 of 361; 69.5%) received upfront surgery as first-line treatment in curative intent. The 5-year OS rate in patients with HPV-positive and HPV-negative tumors were 81.1 and 39.7%, respectively. Upfront surgery in HPV-negative (p < 0.001) and HPV-positive patients (p = 0.05) resulted in improved OS only in advanced stages. Multivariate analysis for patients revealed age in HPV-associated OSCC as an independent predictor for improved survival, and age, performance, N status and therapy as independent predictors in HPV-negative OSCC.
Conclusions: Non-selected OSCC patients amenable to curative therapy show poor 5-year OS. The benefit of upfront surgery remains unclear. A younger patient age was the main factor for a better outcome in patients with HPV-associated OSCC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000477097 | DOI Listing |
Front Immunol
December 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Background: The use of programmed death-1 (PD-1) inhibitors in the neoadjuvant setting for patients with resectable stage III NSCLC has revolutionized this field in recent years. However, there is still 40%-60% of patients do not benefit from this approach. The complex interactions between immune cell subtypes and tertiary lymphoid structures (TLSs) within the tumor microenvironment (TME) may influence prognosis and the response to immunochemotherapy.
View Article and Find Full Text PDFAnn Thorac Surg
December 2024
University of Colorado, Department of Surgery, Division of Cardiothoracic Surgery, Aurora, CO.
Background: Surgical resection is the gold standard treatment for early-stage non-small cell lung cancer (NSCLC). Prior studies have found that delayed treatment carries risk of disease progression. However, factors that predict delay to surgery are relatively understudied.
View Article and Find Full Text PDFUrology
December 2024
Children's Hospital of Philadelphia, Division of Urology.
Uterine RMS is exceedingly rare. The treatment strategy has evolved from aggressive local control with upfront surgery followed by radiation to a more conservative approach with chemotherapy followed by additional treatment pending response, which is outlined in a recent consensus statement from the International Soft-Tissue Sarcoma Consortium. We present a case of a 2-year-old with intermediate risk uterine RMS.
View Article and Find Full Text PDFCureus
December 2024
General Surgery, Sunshine Coast University Hospital, Birtinya, AUS.
Cholecystectomy is one of the most commonly performed surgical operations worldwide. A rare complication following this procedure is the migration of surgical clips used to secure the cystic duct and artery. Herein, we report the migration of a metallic surgical clip into the common bile duct of a 75-year-old gentleman who underwent a laparoscopic cholecystectomy 24 years prior.
View Article and Find Full Text PDFInterdiscip Cardiovasc Thorac Surg
December 2024
Department of Thoracic Surgery, Pasteur 1 Hospital, University Hospital of Nice, Nice, France.
Objectives: The efficacy of neoadjuvant therapy (NT) prior to angioplastic lobectomy (AL) in non-small cell lung cancer is unclear. This study assessed its impact on morbidity, mortality and 5-year survival.
Methods: We retrospectively analysed 114 patients who underwent AL at 2 tertiary centres from January 2000 to December 2020.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!